Topic
Akthelia has secured ISK 180 million to fund preparations for its first clinical trials targeting side effects of cancer treatment, and is seeking further finance for subsequent stages.
A business in Akureyri is reported to be developing drugs targeting global markets valued at over $100 billion annually. Local media suggest it could become the first unicorn from north Iceland’s largest town.
A journalist in Iceland has bought peptides advertised as the weight-management drug Retatrutide, which remains unapproved and in trials. The substances were tested in a laboratory, raising questions about their origin and contents.
The U.S. FDA has approved a new manufacturing method for Simlandi, Alvotech's biosimilar to Humira, allowing the company to scale up production. The news sent Alvotech’s share price up about 7% Tuesday.
